Rayanne da Cunha Mendes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rayanne da Cunha Mendes has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Jordy Silva de Carvalho
Universidade Católica de Pernambuco
2 shared publications - Luis Claudio Almeida da Silva Junior
Universidade Católica de Pernambuco
2 shared publications - Sâmara Pesqueira Souza
Universidade Católica de Pernambuco
2 shared publications - Victor Hugo Oliveira Martins Coelho
Universidade Católica de Pernambuco
2 shared publications - Wagner Gonçalves Horta
Universidade Católica de Pernambuco
2 shared publications
Latest Publications
- Open Access
- 1 January 2024
- Published by Research, Society and Development in Research, Society and Development
- Vol. 13 (1)
Eficácia da pimavanserina para pacientes com psicose na doença de Parkinson: Uma revisão sistemática
The present study aims to evaluate the effectiveness of pimavanserin in patients with psychosis in Parkinson's disease. Its effects on the clinical picture of psychosis were evaluated, as well as its adverse reactions and influences on patients' quality of life. This is a Systematic Literature Review of a qualitative nature, with a search strategy for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Critical Appraisal Skill Program (CASP) methodological evaluation, analyzing a total of 8 articles. Articles were searched in PubMed databases, excluding simple literature reviews and incomplete articles. Those published in the last 10 years (2013-2023) and available in English were included. After a systematic analysis of the studies, it is concluded that pimavanserin demonstrates effectiveness in reducing hallucinogenic and delusional symptoms. Furthermore, it was found that the combination of pimavanserin with other medications, especially clozapine, showed promise in terms of safety, especially in improving cognitive functions. Patients showed improvements in the quality of sleep and wakefulness, in addition to a significant reduction in symptoms. Furthermore, side effects include pneumonia, episodes of syncope, obstructive pulmonary disease, pulmonary embolism and deep vein thrombosis. It is expected that future studies will continue to develop more intervention research on the effectiveness of the medication in treating Parkinson's disease, highlighting benefits and improvements in patients' quality of life through the use of the drug in medical practice.
- 1 January 2024
- Published by Research, Society and Development in Research, Society and Development
- Vol. 13 (1)
Open AccessEficácia da pimavanserina para pacientes com psicose na doença de Parkinson: Uma revisão sistemática
The present study aims to evaluate the effectiveness of pimavanserin in patients with psychosis in Parkinson's disease. Its effects on the clinical picture of psychosis were evaluated, as well as its adverse reactions and influences on patients' quality of life. This is a Systematic Literature Review of a qualitative nature, with a search strategy for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Critical Appraisal Skill Program (CASP) methodological evaluation, analyzing a total of 8 articles. Articles were searched in PubMed databases, excluding simple literature reviews and incomplete articles. Those published in the last 10 years (2013-2023) and available in English were included. After a systematic analysis of the studies, it is concluded that pimavanserin demonstrates effectiveness in reducing hallucinogenic and delusional symptoms. Furthermore, it was found that the combination of pimavanserin with other medications, especially clozapine, showed promise in terms of safety, especially in improving cognitive functions. Patients showed improvements in the quality of sleep and wakefulness, in addition to a significant reduction in symptoms. Furthermore, side effects include pneumonia, episodes of syncope, obstructive pulmonary disease, pulmonary embolism and deep vein thrombosis. It is expected that future studies will continue to develop more intervention research on the effectiveness of the medication in treating Parkinson's disease, highlighting benefits and improvements in patients' quality of life through the use of the drug in medical practice.
- Open Access
- 20 October 2023
- Published by Research, Society and Development in Research, Society and Development
- Vol. 12 (11)
A dieta cetogênica como intervenção para melhoria da qualidade de vida em pacientes diagnosticados com Síndrome de West: Uma revisão sistemática
The present study aims to evaluate the effectiveness of the ketogenic diet in improving the quality of life of patients with West Syndrome, in the control of spasms and convulsions, the benefits of its use alone and as an adjunct to conservative therapies, and its short-term consequences. and long term regarding its tolerance and side effects. This is a Systematic Literature Review of a qualitative nature, with a search strategy for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Critical Appraisal Skill Program (CASP) methodological evaluation, analyzing a total of 6 articles. The articles were searched in the PubMed and SciELO databases, excluding simple literature reviews. Articles published in the last 10 years (2013-2023) and available in English were included. After a systematic analysis of the studies, it appears that the ketogenic diet is effective in reducing infantile spasms, especially in cases refractory to combined drug treatments. In addition, the side effects and relapses to the condition were lower than in patients who used adrenocorticotropic hormone. The Atkins diet approach has also been successful in stopping spasms. The ketogenic diet was well tolerated, with minimal side effects when combined with Vigabatrin. Side effects included increased triglycerides and ketone body. It is hoped that future studies will continue to highlight the benefits and improvements in the quality of life of patients with West Syndrome.
- 20 October 2023
- Published by Research, Society and Development in Research, Society and Development
- Vol. 12 (11)
Open AccessA dieta cetogênica como intervenção para melhoria da qualidade de vida em pacientes diagnosticados com Síndrome de West: Uma revisão sistemática
The present study aims to evaluate the effectiveness of the ketogenic diet in improving the quality of life of patients with West Syndrome, in the control of spasms and convulsions, the benefits of its use alone and as an adjunct to conservative therapies, and its short-term consequences. and long term regarding its tolerance and side effects. This is a Systematic Literature Review of a qualitative nature, with a search strategy for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Critical Appraisal Skill Program (CASP) methodological evaluation, analyzing a total of 6 articles. The articles were searched in the PubMed and SciELO databases, excluding simple literature reviews. Articles published in the last 10 years (2013-2023) and available in English were included. After a systematic analysis of the studies, it appears that the ketogenic diet is effective in reducing infantile spasms, especially in cases refractory to combined drug treatments. In addition, the side effects and relapses to the condition were lower than in patients who used adrenocorticotropic hormone. The Atkins diet approach has also been successful in stopping spasms. The ketogenic diet was well tolerated, with minimal side effects when combined with Vigabatrin. Side effects included increased triglycerides and ketone body. It is hoped that future studies will continue to highlight the benefits and improvements in the quality of life of patients with West Syndrome.